Balancing Risk, Cost, and Access: Early Access Programmes and Competing Policy Objectives in the EU
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Early access is an exception to the general pharmaceutical marketing authorisation procedure that allows for market access in an early stage of development. The criteria for access revolve around the concept of ‘unmet medical need’, which indicates its exceptional character. Its key component is the multitude of actors and policy objectives, whose hierarchy is inverted in relation to the usual circumstances. In parallel, the distribution of competences between Member States and the Union are slightly shifted. This article explores, using early access as the golden middle example, whether the hierarchisation of policy objectives affects the distribution of competences between Member States and the Union, all of this while underlining the potential early access has in the new Pharma Package both independently and as a potential tool of the upcoming sandbox regulatory model.
Fields of Study & Subjects
Healthcare Regulation
Biomedical Ethics and Regulation
Pharmaceutical Economics and Policy
Publication details
- Journal / source
- European Health & Pharmaceutical Law Review
- Volume
- 9
- Issue
- 1
- Pages
- 19–31
- Publication date
- 1 January 2026
- Language
- EN